An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease.
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SLASH-C
- Sponsors Gilead Sciences
- 26 Apr 2016 Status changed from active, no longer recruiting to completed.
- 17 Apr 2016 Results (n=24) presented at The International Liver Congress 2016.
- 04 Nov 2015 Planned End Date changed from 1 Oct 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.